Candida Diagnostic Route AuriFind is a colony/culture classification assay to identify Candida auris, with a granted patent and pending FDA approval, presenting licensing, co-development, or contract testing opportunities with hospitals, clinical labs, and diagnostics companies.

Small Team Needs With a 0-1 employee count, Santa Fe BioLabs is likely to rely on outsourcing and partnerships, creating sales opportunities for contract research, consulting, and lab services to scale discovery, diagnostics, and regulatory efforts.

Diverse Focus Markets The company’s emphasis on antimicrobials, microbial diagnostics, cancer, and healthcare consumer products provides cross-sell opportunities for discovery services, regulatory strategy support, and collaboration with biotech startups and larger industry players.

IP Licensing Potential Patent US 10662405 for AuriFind strengthens the IP position and creates potential for licensing, co-development, or platform integration with diagnostics firms and CROs after regulatory clearance.

Local Ecosystem Access Located in North Texas, the company can leverage regional universities, hospitals, and biotech networks for pilots, clinical validation, and channel partnerships in antimicrobials and diagnostics.